Project ID：DT-202500410-038
Product Brief Summary
- Product Name: A Potential Best-in-Class CDK2 Inhibitor with Better Selectivity, Better Efficacy and Superior PK
- Target: CDK2
- Modality: Small Molecule
- Therapeutic Area: Solid Tumor
- Current Stage: Pre-PCC
- Rights Available: China/Global Right
- Collaboration Mode: License out / co-development
More highlights
- Could solve CDK4/6 resistance by controlling cyclin E-CDK2 activity
- DTC-038 owns better selectivity, better PD activity and superior PK
- DTC-038 owns better AUC and lower clearance than PF-07104091
- Higher drug concentration than PF-07104091 in Breast and Brain
- Currently at pre-PCC stage
Contact us:
For any questions, please contact DrugTimes BD Team at BD@drugtimes.cn, please include Project ID in the subject. Many thanks!
发布者：qi.yang，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
